Global Diabetes Diagnostics Industry

Global Diabetes Diagnostics Industry

  • April 2021 •
  • 609 pages •
  • Report ID: 4368322 •
  • Format: PDF
Abstract:
- Diabetes is the Largest Epidemic in Human History Surpassing Even the Black Death of the 14th Century. Diabetes Diagnostics to Reach a Colossal $45.6Billion
- The global market for Diabetes Diagnostics is projected to reach US$45.6billion by the year 2027, trailing a post COVID-19 CAGR of 8.1% over the analysis period 2020 through 2027. Wiping out over 20% of the world’s population in the 14th century, "Black Death" was the most devastating pandemics in human history. Today type 2 diabetes is gradually emerging into an epidemic much bigger than Black Death. The disease will continue to grow driven by the growing incidence of diabetes in parallel to obesity and the ensuing rise of "diabesity" as a global epidemic; improper lifestyle patterns and the resulting increase in risk factors even among non-obese population. The diagnosis and treatment of diabetes have always been challenging for both the healthcare providers and the patients. Keeping up with regular exercises, diabetic meal plans, medications, and check on blood sugar levels are never easy. Diabetic patients need continuous self-management on a regular basis. It is also a tedious task for the doctors to analyze blood sugar fluctuations and other factors involved in diabetes care. Further in developing economies, managing diabetes and the complications associated with it is a big challenge due to issues such as lack of healthcare professionals, limited access to healthcare facilities, lack of awareness among people and lack of information that enables therapeutic decision-making.
- All these problems contribute to missed diagnosis and delayed visits to the clinics. However, technological advancements are anticipated to solve these problems to a great extent. Advancements in the food and information technologies have revolutionized the diagnosis and treatment of diabetes. Amid the ongoing COVID-19 situation, technology seems to be provided with a chance to prove its worth more than ever before. With the latest technologies in healthcare sector such as food trackers, health apps, glucometers and pedometers, tracking of data has become easy to manage. Technology is expected to bring latest developments particularly during the COVID-19 times, where social distancing is the new norm. Introduction of glucometers, EMRs, mobile apps and digital clinics has made data tracking and lifestyle change much easier. Other technologies such as social media educate and motivate the diabetic patients to bring a change in their lifestyle. The market especially stands to benefit from the rapid advances being made in the field of continuous glucose monitoring such as smart predictive algorithms for automated control; growing understanding of diabetes pathophysiology and the resulting development of more potent disease prevention, control and management strategies; focus on diabetes self-management and research interest in the development of diabetes tracking wearable devices; growing revenue opportunity for mHealth solutions for diabetes diagnosis; launch of implantable continuous glucose monitor and cloud-enabled CGM devices; rising popularity of near patient testing and the resulting demand for HbA1c devices and encouraging research breakthroughs in "artificial pancreas".
- Another worrisome trend positively influencing growth in the market is the increasing incidence of diabetes in children and the resulting focus on shed on timely screening, diagnosis and therapy administration among pediatric patients. Mainstream adoption universal screening for gestational diabetes mellitus (GDM) will also drive revenue opportunities in the market. Asia-Pacific ranks as the fastest growing market led by grim risk population analysis attributable to rapid urbanization, growing affluence and nutrition transition, less physically demanding lifestyles, high prevalence of smoking, alcohol abuse, heavy consumption of refined carbohydrates, lack of exercise and over nutrition. India and China represent the epicenter of the diabetes epidemic with both the countries recording the highest number of diabetics in the region. For long, genes, lifestyle & behavioral change have been in the spotlight as risk factors for developing type 2 diabetes. Currently, epigenetic changes are emerging to be forefront as a possible reason for the rising incidence of type 2 diabetes. While treatment regimes are evolving, routine testing has and will continue to remain vital in effective diabetes management. There is an acute need for easy-to-use, efficient, accurate and affordable solutions for effective management of the disease; and technology innovation and development of non-invasive techniques to simplify regular glucose testing. The most popular home diagnostic device is the blood glucose monitor that assists in detecting the amount of glucose present in blood. A special coated strip containing blood sample is inserted into the machine, which consequently yields results on a digital display. Certain blood glucose monitors are also equipped with a memory component capable of holding multiple test results. Analog glucose monitors are traditional blood glucose meters that uses a blood sample drawn from pricking a patient’s finger.

- Select Competitors (Total 91 Featured) -
  • A.Menarini Diagnostics Ltd.
  • Abbott Diabetes Care, Inc.
  • Acon Laboratories, Inc.
  • AgaMatrix, Inc.
  • Apex Biotechnology Corporation
  • ARKRAY, Inc.
  • Ascensia Diabetes Care Holdings AG
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • BIONIME Corporation
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Beckman Coulter, Inc.
  • HemoCue® AB
  • DexCom, Inc.
  • Diazyme Laboratories Inc.
  • EKF Diagnostics Holdings Plc
  • LifeScan, Inc.
  • Medtronic PLC
  • Nova Biomedical Corporation
  • OSANG Healthcare Co., Ltd.
  • Roche Diabetes Care, Inc.
  • Sanofi S.A.
  • Sanwa Kagaku Kenkyusho Co, Ltd.
  • Siemens Healthineers
  • Sinocare, Inc.
  • PTS Diagnostics
  • Trividia Health, Inc.
  • TaiDoc Technology Corporation
  • Tandem Diabetes Care, Inc.
  • Terumo Corporation
  • Tosoh Bioscience, Inc.
  • Trinity Biotech plc
  • Ypsomed AG